Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of Olutasidenib With Temozolomide as Maintenance Therapy in Pediatric and Young Adult Patients Newly Diagnosed With High-Grade Glioma (HGG), Including Diffuse Intrinsic Pontine Glioma (DIPG), Which Harbor IDH1 Mutations

NCT06161974 is registered in ClinicalTrials.gov with Rigel Pharmaceuticals as lead sponsor.

NCT NCT06161974
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06161974 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of Olutasidenib With Temozolomide as Maintenance Therapy in Pediatric and Young Adult Patients Newly Diagnosed With High-Grade Glioma (HGG), Including Diffuse Intrinsic Pontine Glioma (DIPG), Which Harbor IDH1 Mutations
Lead sponsor
Rigel Pharmaceuticals
Phase
Phase 2
Overall status
Recruiting
Start date
February 1, 2025
Completion date
June 30, 2035
Enrollment
60 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

astrocytoma, astrocytoma, grade iii, astrocytoma, grade iv, diffuse intrinsic pontine glioma, diffuse midline glioma, h3 k27m-mutant, high grade glioma, idh1 mutation, idh1 r132, idh1 r132c, idh1 r132g, idh1 r132h, idh1 r132l, idh1 r132s, metastatic brain tumor, oligodendroglioma, spinal tumor, thalamus tumor, who grade iii glioma, who grade iv glioma